Keywordstenascin C; epidermal growth factor receptor (EGFR); E-cadherin; thyroid transcription factor-1 (TTF-1); medullary thyroid carcinoma; tumor necrosis factor superfamily member 4 (TNFSF4); single nucleotide polymorphism (SNP); autoimmune thyroid diseases (AITDs); Graves’ disease (GD); Hashimoto’s thyroiditis (HT); mitochondrial DNA; mitochondrial DNA copy number; haplogroup; papillary thyroid cancer; papillary thyroid carcinoma; HER2 (Human Epidermal Growth Factor Receptor 2); Telomere; FISH (fluorescence in situ hybridization); sporadic differentiated thyroid cancer; HER2 (Human Epidermal Growth Factor Receptor 2); immunohistochemistry; FISH (fluorescence in situ hybridization); cellular compartments; mass spectrometry; proteomics; pathway analysis; random positioning machine; thyroid cancer; hypertension; vascular endothelial growth factor; multi-kinase inhibitors; lenvatinib; sorafenib; sunitinib; fine needle aspiration cytology (FNAC); indeterminate lesions; next generation sequencing; gene expression classifier; microRNAs (miRNAs); thyroid carcinoma; diffusion weighted imaging; lymphatic metastatic spread; ADC histogram analysis; histopathologic features; Ki-67; p53; RET/PTC gene rearrangement; air-dried FNA specimen; RT-PCR; Nanostring; radiation; thyroid cancer; cancer genes; lipid metabolism; thyroid gland; thyroid cancer; microgravity; hypergravity; space environment; follicular thyroid adenoma; follicular thyroid cancer; gene expression; microarray; meta-analysis; differentiated thyroid cancer; radioiodine therapy; targeted therapy; tyrosine kinase inhibitors; thyroid cancer; p53; p63; p73; genetic alterations; p53 inhibition mechanisms; target therapies; cell-free DNA; integrity index; plasma; qPCR; papillary thyroid carcinoma; n/a
